Sign inSubscribe

target directory

aav2 gdnf gene therapy for parkinsons disease clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT06285643
Source recordAI-normalized

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

AskBio Inc is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of AAV2-GDNF gene therapy in adults with moderate Parkinson's Disease. The trial is randomized, double-blind, and sham-controlled, aiming to enroll approximately 127 participants across multiple sites in the U.S. and Germany.

AI analysis

Indication: Parkinson Disease

Modality: gene therapy

Target: AAV2-GDNF gene therapy for Parkinson's Disease

Sponsor: AskBio Inc

Source URL: ClinicalTrials.gov

Source updated: Dec 08, 2025

Ingested: May 31, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: AAV2-GDNF gene therapy for Parkinson's Disease

View original source fields

Condition raw: Parkinson Disease

Condition normalized: Parkinson Disease

Modality raw: Parkinson Disease

Modality normalized: gene therapy

Target raw: AAV2-GDNF gene therapy for Parkinson's Disease

Target normalized: AAV2-GDNF gene therapy for Parkinson's Disease

Open report